Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine—Burkina Faso, 2011–2013
Kambiré, D, Soeters, HM, Ouédraogo-Traoré, R, Medah, I, Sangare, L, Yaméogo, I, Sawadogo, G, Ouédraogo, A, Hema-Ouangraoua, S, McGee, L, Srinivasan, V, Aké, F, Congo-Ouédraogo, M, Sanou, S, Ky Ba, A, Novak, RT and Van Beneden, C
(2016).
Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine—Burkina Faso, 2011–2013.
[Dataset].
PLOS ONE.
https://doi.org/10.1371/journal.pone.0166384.s001
Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the leading cause of bacterial meningitis in Burkina Faso. We describe bacterial meningitis epidemiology, focusing on pneumococcal meningitis, before 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the pediatric routine immunization program in October 2013.
Additional Information
No LSHTM primary authors. Dataset recorded in LSHTM data repository due to contribution of Brian Greenwood to research. See contributor list)
Keywords
PCV 13-associated serotypes, non-PCV 13-associated serotypes, 13- valent pneumococcal conjugate vaccine, Haemophilus influenzae type b vaccine, meningococcal conjugate vaccine, pneumococcal meningitis, polymerase chain reactionNo files available. Please consult associated links.
Downloads
